A trade organisation representing pharma manufacturers in Europe has said plans to restrict the use of fluorinated substances known as PFAS could make manufacturing “grind to a halt” and ...

Pharmaceutical Social Media: Engage Compliantly & Drive Results! Customer-Centric & Balanced Risk/Reward Approaches To Boost Profits & Compliantly Engage, Influence & Target Patients & HCPs With ...

Merck's $11.5 billion deal to acquire Acceleron last year hinged on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has just hit the spot in a much-anticipated ...

The last few years have been marked by many big pharma companies opting to move away from diversification and towards more focused operations. Ben Hargreaves explores what is driving this ...

Metrics to use to track the 2024 VPAG have been subject to discussions, with reference made to two days where talks were held (17th July and 19th July) in the July VPAG operational review meeting ...

‘Patient-centricity’ is a term that has gained currency in the pharma industry in recent years, and most major companies in the sector are now dedicating resources to ensure that they put the ...

The pharmaceutical construction industry has seen explosive growth, a trend with substantial implications for healthcare industry, and global health outcomes. The COVID-19 pandemic underscored the ...

UK-based life science investor Syncona has launched a new company – Slingshot Therapeutics – with a mission to find promising projects in academia and translate them into full-blown ...

The Republican chair of the Senate Appropriations Committee, Sen Susan Collins, has torn a strip off the Trump administration for policies that she said are putting the US position as a world ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...